Ali Mortazavi, the boss of gene silencing specialist, Silence Therapeutics PLC (LON:SLN), has been appointed as the non-executive chairman of artificial intelligence and healthcare firm, Ultromics.
Ultromics, which was spun out of University of Oxford earlier this year, is a platform technology that extracts thousands of data points from a single image.
It then uses machine learning, a form of AI, to determine which data points are specific to a certain disease.
Currently the technology has been applied to echocardiograms (ECGs) to improve the diagnostic accuracy of coronary artery disease from 80% to greater than 95%.
“Artificial intelligence will increasingly begin to play a bigger role in medicine as well as other sectors,” said Mortazavi in a statement this morning.
“Ultromics plans to use the combination of Man plus machine rather than Man vs machine in medical imaging.”